Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968669 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 329
- Enrollment target
NCT00968669 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 329 participants.
The verdict
NCT00968669, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 329 participants
- Enrollment target
Study Summary
To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI528 30 mg
- BIOLOGICAL MEDI528 100 mg
- BIOLOGICAL MEDI528 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00968669
The ClinicalTrials.gov registry entry for NCT00968669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00968669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00968669 about?
NCT00968669 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults". To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.
What is the current status of trial NCT00968669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 329 participants. The study started on 2009-12. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00968669?
The interventions under investigation include: Placebo (OTHER), MEDI528 30 mg (BIOLOGICAL), MEDI528 100 mg (BIOLOGICAL), MEDI528 300 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00968669?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.